Osteoporosis drug may boost fertility: new study tests denosumab on egg maturation
NCT ID NCT07546552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates whether blocking a protein called RANKL can help eggs mature and improve fertility treatments. Researchers will use denosumab, a drug already approved for osteoporosis, in lab studies with human and mouse eggs. The goal is to understand if RANKL manipulation could lead to better IVF outcomes for women with infertility.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Denosumab
What this could lead to
If successful, this research could point toward new ways to improve IVF success and treat female infertility by targeting RANKL.
What could go wrong
This is early-stage research in mice, human tissue, and a small number of women. It may not lead to a practical treatment, and denosumab's effects on fertility are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regionshospitalet, Skive, Midt Jylland 7800
RECRUITINGSkive, Midt Jylland, 7800, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••